{"title": "Megadosis de metilprednisolona oral frente a intravenosa para el brote de esclerosis m\u00faltiple. Comparaci\u00f3n de la eficacia cl\u00ednica y radiol\u00f3gica", "author": null, "url": "https://portalrecerca.uab.cat/en/studentTheses/megadosis-de-metilprednisolona-oral-frente-a-intravenosa-para-el-", "hostname": "portalrecerca.uab.cat", "description": null, "sitename": "Universitat Aut\u00f2noma de Barcelona Research Portal", "date": "2013-03-14", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Most patients with multiple sclerosis (MS) experience relapses, especially in the initial phases of the disease. The relapses are subacute episodes of neurological deficit with variable recovery. Current MS therapies are based on minimizing the risk of relapses, but none have been able to completely prevent them. Treating relapses, shortening their duration, and promoting recovery remain essential aspects in the care of patients with MS. The literature contains extensive guidelines regarding treatments to modify the natural history of MS, but there are few references about the best treatment for exacerbations. The experts agree that MS relapses should be treated with steroids, but there is no consensus regarding which steroid is optimal for this purpose, the most effective dose, or how long treatment should last. This thesis contains a review of the literature related to the pathophysiology of MS relapse, the guidelines that are applied for relapses, and the mechanisms of action of the treatments used. We report the results of a multi-center, double-blind, randomized clinical trial performed to test the hypothesis that a bioequivalent high dose of methylprednisolone (MP) administered orally, should not be inferior clinically or radiologically to intravenous MP for the treatment of MS relapses. The results show that the oral route is not inferior to the intravenous route for this purpose, and that the safety and tolerability of both administration routes are equal. These findings imply a great benefit for the patients\u2019 quality of life, in addition to healthcare- and work-related savings. We conclude that treatment of MS exacerbations with intravenous MP may not be justified. It is our hope that the results of this study will contribute to changing the treatment paradigm of MS relapses.\n|Date of Award||14 Mar 2013|\n|Original language||Spanish|\n|Supervisor||Joan Costa Pages (Director) & Antonio Davalos Errando (Director)|\nMegadosis de metilprednisolona oral frente a intravenosa para el brote de esclerosis m\u00faltiple. Comparaci\u00f3n de la eficacia cl\u00ednica y radiol\u00f3gica\nRamo Tello, Cristina (Author). 14 Mar 2013\nStudent thesis: Doctoral thesis\nAuthor: Ramo Tello, Cristina , 14 Mar 2013\nSupervisor: Costa Pages, J. (Director) & Davalos Errando, A. (Director)\nStudent thesis: Doctoral thesis\nStudent thesis: Doctoral thesis", "language": null, "image": "https://portalrecerca.uab.cat/skin/headerImage/", "pagetype": "website", "links": ["#main-navigation", "#main-search", "#main-content", "/en/", "https://www.uab.cat/web/investigar/itineraris/eines-i-suport-a-la-recerca/egreta-entorn-per-a-la-gestio-de-la-recerca-i-la-transferencia-1345808184219.html", "/en/", "/en/persons/", "/en/organisations/", "/en/projects/", "/en/publications/", "/en/datasets/", "/en/studentTheses/", "https://portalrecerca.uab.cat/en/organisations/department-of-medicine", "https://portalrecerca.uab.cat/en/studentTheses/megadosis-de-metilprednisolona-oral-frente-a-intravenosa-para-el-", "https://portalrecerca.uab.cat/en/studentTheses/megadosis-de-metilprednisolona-oral-frente-a-intravenosa-para-el-", "http://hdl.handle.net/10803/117216", "https://ddd.uab.cat/record/113027", "https://www.facebook.com/sharer.php?u=https://portalrecerca.uab.cat/en/studentTheses/megadosis-de-metilprednisolona-oral-frente-a-intravenosa-para-el-%3Futm_source%3Dfacebook%26utm_medium%3Dsocial%26utm_campaign%3Dsharelink&p[summary]=Check+out+this+student+thesis+at+Universitat+Aut%C3%B2noma+de+Barcelona+Research+Portal+%3A+Megadosis+de+metilprednisolona+oral+frente+a+intravenosa+para+el+brote+de+esclerosis+m%C3%BAltiple.+Comparaci%C3%B3n+de+la+eficacia+cl%C3%ADnica+y+radiol%C3%B3gica", "https://twitter.com/intent/tweet?url=https://portalrecerca.uab.cat/en/studentTheses/megadosis-de-metilprednisolona-oral-frente-a-intravenosa-para-el-%3Futm_source%3Dtwitter%26utm_medium%3Dsocial%26utm_campaign%3Dsharelink&text=Check+out+this+student+thesis+at+Universitat+Aut%C3%B2noma+de+Barcelona+Research+Portal+%3A+Megadosis+de+metilprednisolona+oral+frente+a+intravenosa+para+el+brote+de+esclerosis+m%C3%BAltiple.+Comparaci%C3%B3n+de+la+eficacia+cl%C3%ADnica+y+radiol%C3%B3gica", "https://www.linkedin.com/shareArticle?mini=true&url=https://portalrecerca.uab.cat/en/studentTheses/megadosis-de-metilprednisolona-oral-frente-a-intravenosa-para-el-%3Futm_source%3Dlinkedin%26utm_medium%3Dsocial%26utm_campaign%3Dsharelink&summary=Check+out+this+student+thesis+at+Universitat+Aut%C3%B2noma+de+Barcelona+Research+Portal+%3A+Megadosis+de+metilprednisolona+oral+frente+a+intravenosa+para+el+brote+de+esclerosis+m%C3%BAltiple.+Comparaci%C3%B3n+de+la+eficacia+cl%C3%ADnica+y+radiol%C3%B3gica", "mailto:?subject=Megadosis%20de%20metilprednisolona%20oral%20frente%20a%20intravenosa%20para%20el%20brote%20de%20esclerosis%20m%C3%BAltiple.%20Comparaci%C3%B3n%20de%20la%20eficacia%20cl%C3%ADnica%20y%20radiol%C3%B3gica&body=Check%20out%20this%20student%20thesis%20at%20Universitat%20Aut%C3%B2noma%20de%20Barcelona%20Research%20Portal%20%3A%20Megadosis%20de%20metilprednisolona%20oral%20frente%20a%20intravenosa%20para%20el%20brote%20de%20esclerosis%20m%C3%BAltiple.%20Comparaci%C3%B3n%20de%20la%20eficacia%20cl%C3%ADnica%20y%20radiol%C3%B3gica | https://portalrecerca.uab.cat/en/studentTheses/megadosis-de-metilprednisolona-oral-frente-a-intravenosa-para-el-?utm_source=email&utm_medium=email&utm_campaign=sharelink", "http://www.elsevier.com/online-tools/research-intelligence/products-and-services/pure", "http://www.scopus.com/", "http://www.elsevier.com/online-tools/research-intelligence/products-and-services/elsevier-fingerprint-engine", "http://www.elsevier.com", "/en/about/cookies/", "https://egreta.uab.cat/admin/workspace.xhtml", "https://www.uab.cat/web/la-uab/itineraris/proteccio-de-dades-1345668257177.html", "/en/web-accessibility/", "mailto:egreta@uab.cat", "#"]}